View in EDS

Synergistic targeting of the ARID2-MYC axis by pomalidomide and panobinostat overcomes intrinsic IMiD resistance in multiple myeloma.

Saved in:
Bibliographic Details
Title: Synergistic targeting of the ARID2-MYC axis by pomalidomide and panobinostat overcomes intrinsic IMiD resistance in multiple myeloma.
Authors: Yamamoto J; School of Life Science and Technology, Institute of Science Tokyo, Yokohama, 226-8501, Japan. yamamoto.j.0c42@m.isct.ac.jp., Asatsuma-Okumura T; Department of Cell Biology, Institute of Advanced Medical Sciences, Graduate School of Medicine, Nippon Medical School, Bunkyo, 113-8602, Japan., Ito T; Institute of Medical Science, Tokyo Medical University, Shinjuku, 160-8402, Japan., Iwai Y; Department of Cell Biology, Institute of Advanced Medical Sciences, Graduate School of Medicine, Nippon Medical School, Bunkyo, 113-8602, Japan., Handa H; Department of Molecular Pharmacology, Center for Future Medical Research, Institute of Medical Science, Tokyo Medical University, Shinjuku, 160-8402, Japan., Yamaguchi Y; School of Life Science and Technology, Institute of Science Tokyo, Yokohama, 226-8501, Japan.
Source: Scientific reports [Sci Rep] 2026 Feb 05; Vol. 16 (1). Date of Electronic Publication: 2026 Feb 05.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2045-2322
DOI:10.1038/s41598-026-37740-3